7Baggers

Elanco Animal Health Incorporated
(NYSE:ELAN) 

ELAN stock logo

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto...

Founded: 1954
Full Time Employees: 6,080
CEO: Jeff Simmons  
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
                                   
      revenue
    		1,371,000,000 1,144,000,000 1,137,000,000 1,241,000,000 1,193,000,000 1,020,000,000 1,030,000,000 1,184,000,000 1,205,000,000 1,035,000,000 1,068,000,000 1,057,000,000 1,257,000,000 981,000,000 1,028,000,000 1,177,000,000 1,225,000,000 1,113,000,000 1,131,000,000 1,279,000,000 1,242,000,000 1,139,700,000 889,600,000 586,300,000 657,700,000 787,000,000 771,300,000 781,600,000 731,100,000 799,300,000 761,100,000 
      yoy
    		14.92% 12.16% 10.39% 4.81% -1.00% -1.45% -3.56% 12.02% -4.14% 5.50% 3.89% -10.20% 2.61% -11.86% -9.11% -7.97% -1.37% -2.34% 27.14% 118.15% 88.84% 44.82% 15.34% -24.99% -10.04% -1.54% 1.34%     
      qoq
    		19.84% 0.62% -8.38% 4.02% 16.96% -0.97% -13.01% -1.74% 16.43% -3.09% 1.04% -15.91% 28.13% -4.57% -12.66% -3.92% 10.06% -1.59% -11.57% 2.98% 8.98% 28.11% 51.73% -10.86% -16.43% 2.04% -1.32% 6.91% -8.53% 5.02%  
      cost of sales
    		586,000,000 555,000,000 530,000,000 528,000,000 509,000,000 501,000,000 492,000,000 495,000,000 515,000,000 516,000,000 487,000,000 434,000,000 494,000,000 448,000,000 472,000,000 484,000,000 509,000,000 512,000,000 502,000,000 551,000,000 569,000,000 596,200,000 441,800,000 295,900,000 332,700,000 410,100,000 360,400,000 356,000,000 343,800,000 412,500,000 369,800,000 
      gross profit
    		785,000,000 589,000,000 607,000,000 713,000,000 684,000,000                           
      yoy
    		14.77%                               
      qoq
    		33.28% -2.97% -14.87% 4.24%                            
      gross margin %
    		57.26% 51.49% 53.39% 57.45% 57.33% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
      research and development
    		97,000,000 93,000,000 89,000,000 92,000,000 94,000,000 81,000,000 87,000,000 89,000,000 87,000,000 79,000,000 86,000,000 81,000,000 81,000,000 80,000,000 78,000,000 82,000,000 81,000,000 92,000,000 94,000,000 94,000,000 89,000,000 112,700,000 88,100,000 59,400,000 66,800,000 67,300,000 69,900,000 68,800,000 64,100,000 61,100,000 58,900,000 
      marketing, selling and administrative
    		381,000,000 338,000,000 351,000,000 400,000,000 341,000,000 300,000,000 323,000,000 354,000,000 337,000,000 292,000,000 313,000,000 353,000,000 327,000,000 304,000,000 298,000,000 343,000,000 320,000,000 329,000,000 342,000,000 385,000,000 348,000,000 374,100,000 277,700,000 162,800,000 182,000,000 185,900,000 192,300,000 200,900,000 181,100,000 185,100,000 179,000,000 
      amortization of intangible assets
    		138,000,000 139,000,000 140,000,000 136,000,000 128,000,000 130,000,000 133,000,000 131,000,000 133,000,000 138,000,000 140,000,000 136,000,000 134,000,000 130,000,000 128,000,000 133,000,000 137,000,000 139,000,000 141,000,000 129,000,000 147,000,000 163,700,000 95,600,000 49,000,000 51,600,000 51,400,000 50,700,000 49,300,000 49,000,000 50,100,000 48,700,000 
      asset impairment, restructuring and other special charges
    		16,000,000 202,000,000 25,000,000 1,000,000 9,000,000 7,000,000 17,000,000 80,000,000 46,000,000 36,000,000 16,000,000 35,000,000 40,000,000 25,000,000 26,000,000 86,000,000 46,000,000 110,000,000 111,000,000 299,000,000 108,000,000 167,300,000 262,200,000 119,400,000 74,800,000 51,600,000 77,200,000 31,800,000    
      interest expense, net of capitalized interest
    		57,000,000 80,000,000 52,000,000 48,000,000 40,000,000 46,000,000 58,000,000 65,000,000 66,000,000 67,000,000 72,000,000 74,000,000 64,000,000 62,000,000 60,000,000 67,000,000 52,000,000 55,000,000 60,000,000 60,000,000 61,000,000 60,400,000 48,100,000 24,800,000 16,500,000 18,700,000 18,700,000 20,700,000 20,800,000   
      other expense
    		9,000,000 -4,000,000  11,000,000 12,000,000 6,000,000 1,000,000 2,000,000 9,000,000 34,000,000 9,000,000 23,000,000 9,000,000 15,000,000 8,000,000  9,000,000 -3,000,000 11,000,000             
      income before income taxes
    		87,000,000 -259,000,000 -50,000,000 25,000,000 60,000,000 -51,000,000 559,000,000 -32,000,000 12,000,000 -127,000,000 -1,097,000,000 -79,000,000 108,000,000 -83,000,000 -42,000,000 -18,000,000 71,000,000 -121,000,000 -130,000,000 -236,000,000 -80,000,000 -318,100,000 -209,000,000 -77,100,000 -67,800,000 -4,300,000 -12,500,000 50,200,000 44,800,000 -2,200,000 78,800,000 
      income tax expense
    		30,000,000 17,000,000 -16,000,000 14,000,000  -43,000,000 195,000,000 18,000,000 -20,000,000 14,000,000 -1,000,000 18,000,000 5,000,000 -28,000,000 7,000,000 4,000,000 23,000,000     4,700,000 -74,000,000 -23,900,000 -18,700,000 5,200,000 -22,500,000 14,300,000 13,300,000 -18,600,000 18,600,000 
      net income
    		57,000,000 -276,000,000 -34,000,000 11,000,000 67,000,000 -8,000,000 364,000,000 -50,000,000 32,000,000 -141,000,000 -1,096,000,000 -97,000,000 103,000,000 -55,000,000 -49,000,000 -22,000,000 48,000,000 -97,000,000 -104,000,000 -210,000,000 -61,000,000 -322,800,000 -135,000,000 -53,200,000 -49,100,000 -9,500,000 10,000,000 35,900,000 31,500,000 16,400,000 60,200,000 
      yoy
    		-14.93% 3350.00% -109.34% -122.00% 109.38% -94.33% -133.21% -48.45% -68.93% 156.36% 2136.73% 340.91% 114.58% -43.30% -52.88% -89.52% -178.69% -69.95% -22.96% 294.74% 24.24% 3297.89% -1450.00% -248.19% -255.87% -157.93% -83.39%     
      qoq
    		-120.65% 711.76% -409.09% -83.58% -937.50% -102.20% -828.00% -256.25% -122.70% -87.14% 1029.90% -194.17% -287.27% 12.24% 122.73% -145.83% -149.48% -6.73% -50.48% 244.26% -81.10% 139.11% 153.76% 8.35% 416.84% -195.00% -72.14% 13.97% 92.07% -72.76%  
      net income margin %
    		4.16% -24.13% -2.99% 0.89% 5.62% -0.78% 35.34% -4.22% 2.66% -13.62% -102.62% -9.18% 8.19% -5.61% -4.77% -1.87% 3.92% -8.72% -9.20% -16.42% -4.91% -28.32% -15.18% -9.07% -7.47% -1.21% 1.30% 4.59% 4.31% 2.05% 7.91% 
      earnings per share:
    		                               
      basic
    		0.11 -0.56 -0.07 0.02 0.14 -0.02 0.74 -0.1 0.06   -0.2 0.21   -0.04 0.1     -0.71 -0.29 -0.13 -0.12 -0.03 0.03 0.1 0.09   
      diluted
    		0.11 -0.56 -0.07 0.02 0.13 -0.02 0.73 -0.1 0.06   -0.2 0.21   -0.04 0.1     -0.71 -0.29 -0.13 -0.12 -0.03 0.03 0.1 0.09   
      weighted-average shares outstanding:
    		                               
      basic
    		497.7 496.4 496.8 496.6 495.1 494 494.3 494.2 493.2 492.3 492.7 492.6 491.1 488.3 488.4 488.4 488 487.2 487.3 487.3 486.7 441.4 462.4 413.2 403.9 369 371.6 365.7 365.7   
      diluted
    		506 496.4 496.8 500.1 499.1 497.3 497.7 494.2 496 492.3 492.7 492.6 492.8 488.3 488.4 488.4 492.2 487.2 487.3 487.3 486.7 441.4 462.4 413.2 403.9 370.3 373.2 367 366   
      gain on divestiture
    		      -640,000,000                         
      income tax benefit
    		    -7,000,000             -17,750,000 -26,000,000 -26,000,000 -19,000,000           
      costs, expenses and other:
    		                               
      goodwill impairment
    		          1,042,000,000                     
      costs, expenses and other: - sum
    		     1,071,000,000 471,000,000 1,216,000,000 1,193,000,000 1,162,000,000 2,165,000,000 1,136,000,000 1,149,000,000 1,064,000,000 1,070,000,000 1,195,000,000 1,154,000,000 1,234,000,000 1,261,000,000 1,515,000,000 1,322,000,000           
      loss per share:
    		                               
      basic
    		         -0.29 -2.22   -0.11 -0.1   -0.193 -0.21 -0.43 -0.12           
      diluted
    		         -0.29 -2.22   -0.11 -0.1   -0.193 -0.21 -0.43 -0.12           
      other income
    		                   -3,000,000            
      other–net, expense
    		                     -40,425,000 -114,900,000 -47,900,000 1,100,000 5,275,000 14,600,000 3,900,000 2,600,000 6,050,000 13,500,000 
      asset impairments, restructuring and other special charges
    		                            24,900,000 46,000,000 12,400,000 
      earnings per share:
    		                               
      basic and diluted
    		                             0.09 0.16 
      weighted-average shares outstanding:
    		                               
      basic and diluted
    		                             313.7 365.6 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
                                     
        assets
      		                               
        current assets
      		                               
        cash and cash equivalents
      		428,000,000 545,000,000 505,000,000 539,000,000 487,000,000 468,000,000 490,000,000 416,000,000 345,000,000 352,000,000 369,000,000 367,000,000 318,000,000 345,000,000 460,000,000 507,000,000 342,000,000 638,000,000 453,000,000 580,000,000 515,000,000 494,700,000 659,900,000 1,391,100,000 1,206,400,000 334,000,000 309,200,000 385,100,000 272,100,000 474,800,000 300,000,000 
        accounts receivable
      		1,084,000,000 873,000,000 894,000,000 989,000,000 970,000,000 805,000,000 840,000,000 999,000,000 988,000,000 842,000,000 911,000,000 1,000,000,000 1,051,000,000 797,000,000 804,000,000 916,000,000 973,000,000 833,000,000 924,000,000 1,067,000,000 1,028,000,000 871,600,000 762,300,000 543,900,000 676,800,000 816,900,000 758,300,000 757,200,000 684,100,000 651,800,000 606,100,000 
        other receivables
      		70,000,000 67,000,000 81,000,000 114,000,000 90,000,000 81,000,000 64,000,000 81,000,000 90,000,000 168,000,000 224,000,000 225,000,000 213,000,000 205,000,000 224,000,000 212,000,000 219,000,000 195,000,000 158,000,000 107,000,000 104,000,000 205,100,000 70,800,000 72,900,000 66,900,000 73,000,000 65,100,000 74,300,000 107,800,000 57,600,000 30,800,000 
        inventories
      		1,717,000,000 1,737,000,000 1,708,000,000 1,670,000,000 1,592,000,000 1,574,000,000 1,632,000,000 1,611,000,000 1,638,000,000 1,735,000,000 1,690,000,000 1,690,000,000 1,596,000,000 1,538,000,000 1,340,000,000 1,334,000,000 1,345,000,000 1,373,000,000 1,383,000,000 1,450,000,000 1,424,000,000 1,578,100,000 1,597,100,000 1,065,300,000 1,019,000,000 1,050,700,000 1,068,700,000 1,053,100,000 1,035,500,000 1,004,100,000 1,008,700,000 
        prepaid expenses and other
      		285,000,000 236,000,000 305,000,000 302,000,000 301,000,000 287,000,000 340,000,000 277,000,000 338,000,000 310,000,000 371,000,000 370,000,000 370,000,000 394,000,000 326,000,000 338,000,000 315,000,000 237,000,000 242,000,000 227,000,000 273,000,000 256,300,000 180,600,000 107,400,000 132,100,000 87,400,000 98,000,000 102,300,000 114,800,000 113,900,000 123,200,000 
        total current assets
      		3,584,000,000 3,458,000,000 3,493,000,000 3,614,000,000 3,440,000,000 3,215,000,000 3,366,000,000 4,011,000,000 4,050,000,000 3,407,000,000 3,565,000,000 3,652,000,000 3,548,000,000 3,279,000,000 3,154,000,000 3,307,000,000 3,194,000,000 3,276,000,000 3,160,000,000 3,431,000,000 3,344,000,000 3,416,500,000 3,281,400,000 3,191,300,000 3,120,600,000 2,373,100,000 2,310,400,000 2,383,500,000 2,278,300,000 2,504,900,000 2,703,700,000 
        noncurrent assets
      		                               
        property and equipment
      		1,395,000,000 1,409,000,000 1,392,000,000 1,357,000,000 1,047,000,000 993,000,000 979,000,000 949,000,000 949,000,000 1,026,000,000 992,000,000 1,007,000,000 1,000,000,000 999,000,000 936,000,000 961,000,000 987,000,000 1,061,000,000 1,041,000,000 1,033,000,000 1,271,000,000 1,316,300,000 1,242,500,000 924,100,000 930,100,000 955,300,000 911,700,000 931,100,000 930,200,000 922,400,000 909,300,000 
        goodwill
      		4,723,000,000 4,779,000,000 4,764,000,000 4,758,000,000 4,508,000,000 4,414,000,000 4,625,000,000 4,480,000,000 4,478,000,000 5,094,000,000 4,902,000,000 6,040,000,000 6,061,000,000 5,993,000,000 5,716,000,000 5,898,000,000 6,116,000,000 6,172,000,000 6,191,000,000 6,239,000,000 6,016,000,000 6,224,800,000 6,434,700,000 3,044,000,000 3,004,000,000 2,989,600,000 2,946,400,000 2,959,600,000 2,933,100,000 2,958,000,000 2,968,800,000 
        other intangibles
      		3,225,000,000 3,408,000,000 3,596,000,000 3,705,000,000 3,634,000,000 3,681,000,000 4,011,000,000 4,000,000,000 4,196,000,000 4,494,000,000 4,475,000,000 4,678,000,000 4,791,000,000 4,842,000,000 4,766,000,000 5,059,000,000 5,395,000,000 5,587,000,000 5,816,000,000 5,755,000,000 6,032,000,000 6,387,300,000 5,785,600,000 2,432,700,000 2,455,500,000 2,482,800,000 2,435,000,000 2,352,800,000 2,386,500,000 2,453,000,000 2,514,800,000 
        other noncurrent assets
      		295,000,000 304,000,000 306,000,000 308,000,000 312,000,000 311,000,000 302,000,000 324,000,000 346,000,000 341,000,000 410,000,000 419,000,000 369,000,000 378,000,000 376,000,000 376,000,000 559,000,000 387,000,000 357,000,000 375,000,000 325,000,000 347,800,000 492,800,000 283,900,000 217,000,000 185,000,000 220,200,000 229,900,000 219,300,000 103,100,000 100,000,000 
        total assets
      		13,222,000,000 13,358,000,000 13,551,000,000 13,742,000,000 12,941,000,000 12,614,000,000 13,283,000,000 13,764,000,000 14,019,000,000 14,362,000,000 14,344,000,000 15,796,000,000 15,769,000,000 15,491,000,000 14,948,000,000 15,601,000,000 16,251,000,000 16,483,000,000 16,565,000,000 16,833,000,000 16,988,000,000 17,692,700,000 17,237,000,000 9,876,000,000 9,727,200,000 8,985,800,000 8,823,700,000 8,856,900,000 8,747,400,000 8,956,700,000 9,211,500,000 
        liabilities and equity
      		                               
        current liabilities
      		                               
        accounts payable
      		372,000,000 368,000,000 352,000,000 368,000,000 330,000,000 296,000,000 259,000,000 291,000,000 302,000,000 270,000,000 296,000,000 354,000,000 381,000,000 390,000,000 350,000,000 386,000,000 402,000,000 418,000,000 436,000,000 506,000,000 411,000,000 501,000,000 355,900,000 242,500,000 215,000,000 222,600,000 206,100,000 242,900,000 252,100,000 205,200,000 202,700,000 
        sales rebates and discounts
      		400,000,000 416,000,000 376,000,000 367,000,000 319,000,000 332,000,000 333,000,000 356,000,000 318,000,000 367,000,000 356,000,000 332,000,000 329,000,000 324,000,000 298,000,000 284,000,000 295,000,000 316,000,000 316,000,000 303,000,000 331,000,000 295,300,000 278,600,000 164,000,000 192,700,000 211,000,000 182,200,000 176,000,000 171,700,000 169,900,000 147,900,000 
        current portion of long-term debt and finance lease liability
      		73,000,000 74,000,000 62,000,000 61,000,000                            
        other current liabilities
      		817,000,000 533,000,000 665,000,000 596,000,000 576,000,000 466,000,000 685,000,000 510,000,000 574,000,000 409,000,000 574,000,000 559,000,000 377,000,000 454,000,000 435,000,000 499,000,000 438,000,000 430,000,000 390,000,000 502,000,000 573,000,000 576,900,000 531,900,000 321,700,000 217,600,000 244,400,000 181,500,000 205,400,000 191,200,000 199,000,000 178,600,000 
        total current liabilities
      		1,662,000,000 1,597,000,000 1,455,000,000 1,392,000,000 1,269,000,000 1,315,000,000 1,321,000,000 1,370,000,000 1,232,000,000 1,241,000,000 1,265,000,000 1,284,000,000 1,578,000,000 1,702,000,000 1,613,000,000 1,338,000,000 1,307,000,000 1,643,000,000 1,362,000,000 1,990,000,000 2,034,000,000 2,076,300,000 1,871,200,000 835,400,000 707,500,000 818,500,000 741,500,000 777,500,000 708,200,000 970,700,000 1,245,400,000 
        noncurrent liabilities
      		                               
        long-term debt and finance lease liability
      		3,918,000,000 3,943,000,000 3,962,000,000 4,148,000,000                            
        liability for sale of future revenue
      		309,000,000 304,000,000 300,000,000 293,000,000                            
        deferred taxes
      		366,000,000 382,000,000 478,000,000 496,000,000 481,000,000 449,000,000 539,000,000 524,000,000 530,000,000 567,000,000 643,000,000 658,000,000 663,000,000 662,000,000 618,000,000 620,000,000 747,000,000 745,000,000 726,000,000 767,000,000 828,000,000 900,300,000 823,100,000 65,500,000 90,200,000 100,800,000 81,100,000 147,800,000 131,800,000 114,600,000 125,000,000 
        other noncurrent liabilities
      		467,000,000 427,000,000 607,000,000 638,000,000 487,000,000 302,000,000 587,000,000 465,000,000 474,000,000 411,000,000 432,000,000 411,000,000 245,000,000 229,000,000 225,000,000 242,000,000 242,000,000 261,000,000 220,000,000 237,000,000 247,000,000 322,100,000 312,900,000 208,900,000 150,300,000 106,600,000 96,400,000 175,700,000 168,400,000 121,500,000 89,500,000 
        total liabilities
      		6,722,000,000 6,811,000,000 6,802,000,000 6,967,000,000 6,588,000,000 6,518,000,000 6,760,000,000 7,822,000,000 7,963,000,000 8,139,000,000 8,210,000,000 8,376,000,000 8,289,000,000 8,202,000,000 8,203,000,000 8,461,000,000 8,639,000,000 8,945,000,000 8,883,000,000 8,853,000,000 8,981,000,000 9,216,800,000 8,892,800,000 3,224,100,000 3,065,700,000 3,438,900,000 3,336,000,000 3,591,400,000 3,551,200,000 3,759,200,000 4,074,400,000 
        commitments and contingencies
      		                               
        equity
      		                               
        preferred stock, 1,000,000,000 shares authorized, no par value; none issued
      		                               
        common stock
      		                               
        additional paid-in capital
      		8,858,000,000 8,870,000,000 8,854,000,000 8,839,000,000 8,819,000,000 8,817,000,000 8,804,000,000 8,790,000,000 8,777,000,000 8,777,000,000 8,763,000,000 8,752,000,000 8,744,000,000 8,738,000,000 8,724,000,000 8,712,000,000 8,699,000,000 8,696,000,000 8,680,000,000 8,663,000,000 8,647,000,000 8,650,100,000 8,620,400,000 6,886,100,000 6,870,300,000 5,636,300,000 5,646,400,000 5,396,500,000 5,398,700,000 5,403,300,000 5,347,400,000 
        accumulated deficit
      		-2,125,000,000 -2,182,000,000 -1,906,000,000 -1,872,000,000 -1,883,000,000 -1,950,000,000 -1,942,000,000 -2,306,000,000 -2,256,000,000 -2,288,000,000 -2,147,000,000 -1,051,000,000 -954,000,000 -1,057,000,000 -972,000,000 -923,000,000 -901,000,000 -949,000,000 -852,000,000 -748,000,000 -538,000,000           
        accumulated other comprehensive loss
      		-233,000,000 -141,000,000 -199,000,000 -192,000,000 -583,000,000 -771,000,000 -339,000,000 -542,000,000 -465,000,000 -266,000,000 -482,000,000 -281,000,000 -310,000,000 -392,000,000 -1,007,000,000 -649,000,000 -186,000,000      -121,800,000 -214,800,000 -242,600,000 -173,700,000 -252,500,000 -214,800,000 -250,400,000 -222,200,000 -210,300,000 
        total equity
      		6,500,000,000 6,547,000,000 6,749,000,000 6,775,000,000 6,353,000,000 6,096,000,000 6,523,000,000 5,942,000,000 6,056,000,000 6,223,000,000 6,134,000,000 7,420,000,000 7,480,000,000 7,289,000,000 6,745,000,000 7,140,000,000 7,612,000,000 7,538,000,000 7,682,000,000 7,980,000,000 8,007,000,000 8,475,900,000 8,344,200,000 6,651,900,000 6,661,500,000 5,546,900,000 5,487,700,000 5,265,500,000 5,196,200,000 5,197,500,000 5,137,100,000 
        total liabilities and equity
      		13,222,000,000 13,358,000,000 13,551,000,000 13,742,000,000 12,941,000,000 12,614,000,000 13,283,000,000 13,764,000,000 14,019,000,000 14,362,000,000 14,344,000,000 15,796,000,000 15,769,000,000 15,491,000,000 14,948,000,000 15,601,000,000 16,251,000,000 16,483,000,000 16,565,000,000 16,833,000,000 16,988,000,000 17,692,700,000 17,237,000,000 9,876,000,000 9,727,200,000 8,985,800,000 8,823,700,000 8,856,900,000 8,747,400,000 8,956,700,000 9,211,500,000 
        employee compensation
      		 206,000,000    177,000,000    157,000,000   110,000,000 146,000,000 136,000,000 113,000,000 111,000,000 185,000,000 159,000,000 124,000,000 114,000,000 143,600,000 139,900,000 57,200,000 56,200,000 99,600,000 88,800,000 67,300,000 64,200,000 98,900,000 81,300,000 
        accrued retirement benefits
      		 158,000,000    175,000,000    184,000,000   164,000,000 161,000,000 240,000,000 254,000,000 270,000,000 271,000,000 302,000,000 317,000,000 316,000,000 345,700,000 299,100,000 83,900,000 82,100,000 82,500,000 81,400,000 108,400,000 106,200,000 109,100,000 136,000,000 
        current portion of long-term debt
      		    44,000,000 44,000,000 44,000,000 213,000,000 38,000,000 38,000,000 39,000,000 39,000,000 381,000,000 388,000,000 394,000,000 56,000,000 61,000,000 294,000,000 61,000,000 555,000,000 605,000,000 554,500,000 553,600,000 25,900,000 26,000,000  24,500,000 27,100,000 29,000,000   
        long-term debt
      		    4,351,000,000 4,277,000,000 4,313,000,000 5,463,000,000 5,727,000,000 5,736,000,000 5,870,000,000 6,023,000,000 5,639,000,000 5,448,000,000 5,507,000,000 6,007,000,000 6,073,000,000 6,025,000,000 6,273,000,000 5,542,000,000 5,556,000,000 5,572,400,000 5,586,500,000 2,030,400,000 2,035,600,000 2,330,500,000 2,335,600,000 2,382,000,000 2,436,600,000 2,443,300,000 2,478,500,000 
        assets held for sale
      		       627,000,000 651,000,000                       
        preferred stock, no par value, 1,000,000,000 shares authorized; none issued
      		                               
        restricted cash
      		                     10,700,000 10,700,000 10,700,000 10,700,000 11,100,000 11,100,000 11,500,000 28,500,000 202,700,000 634,900,000 
        accumulated other comprehensive income
      		                 -209,000,000 -146,000,000 65,000,000 -102,000,000 303,000,000          
        payable to lilly
      		                     5,000,000 11,300,000 24,100,000  16,400,000 58,400,000 58,800,000  268,700,000 634,900,000 
        retained earnings
      		                     -477,200,000 -154,400,000 -19,400,000 33,800,000 84,300,000 93,800,000 83,800,000 47,900,000 16,400,000  
        receivable from lilly
      		                        8,700,000    35,500,000   
        current portion of long term debt
      		                         24,500,000    29,000,000  
        investments
      		                             15,300,000 14,900,000 
        net parent company investment
      		                               
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 
                                      
          cash flows from operating activities
        		                              
          net income
        		57,000,000 -276,000,000 -34,000,000 11,000,000 67,000,000 -8,000,000 364,000,000 -50,000,000 32,000,000   -97,000,000 103,000,000   -22,000,000 48,000,000     -322,800,000 -135,000,000 -53,200,000 -49,100,000 -9,500,000 10,000,000 35,900,000 31,500,000  
          adjustments to reconcile net income to cash flows from operating activities:
        		                              
          depreciation and amortization
        		172,000,000 174,000,000 176,000,000 169,000,000 161,000,000 164,000,000 170,000,000 162,000,000 166,000,000 171,000,000 173,000,000 177,000,000 173,000,000 168,000,000 167,000,000 171,000,000 176,000,000 174,000,000 170,000,000 170,000,000 202,000,000 222,200,000 132,300,000 80,900,000 81,500,000 83,400,000 78,700,000 69,300,000 83,100,000 73,700,000 
          stock-based compensation expense
        		21,000,000 16,000,000 17,000,000 20,000,000 15,000,000 15,000,000 15,000,000 14,000,000 11,000,000 15,000,000 10,000,000 9,000,000 12,000,000 15,000,000 13,000,000 17,000,000 14,000,000 18,000,000 17,000,000 16,000,000 15,000,000 16,600,000 11,700,000 8,300,000 11,100,000 12,700,000 14,800,000 14,200,000 7,700,000 5,800,000 
          sold portion of royalty revenue
        		-9,000,000 -9,000,000 -6,000,000                            
          interest on liability for sale of future revenue
        		14,000,000 13,000,000 13,000,000                            
          changes in operating assets and liabilities, net of divestitures
        		-263,000,000                              
          other non-cash operating activities
        		21,000,000 52,000,000 -30,000,000 -18,000,000 -10,000,000 57,000,000 -15,000,000 -9,000,000 -30,000,000 17,000,000 -20,000,000 10,000,000 2,000,000 -13,000,000 -10,000,000 8,000,000 13,000,000 -1,000,000   10,000,000 -28,900,000 44,000,000 5,100,000 -500,000 7,300,000 2,600,000 -13,200,000 -9,400,000 45,500,000 
          net cash from operating activities
        		13,000,000 108,000,000 219,000,000 237,000,000 -4,000,000 177,000,000 162,000,000 200,000,000 2,000,000 157,000,000 198,000,000 61,000,000 -145,000,000 13,000,000 189,000,000 312,000,000 -62,000,000 223,000,000 89,000,000 149,000,000 22,000,000 -92,900,000 -111,700,000 159,300,000 4,300,000 126,300,000 39,600,000 52,600,000 5,600,000 139,500,000 
          capital expenditures
        		-51,000,000 -62,000,000 -92,000,000 -57,000,000 -65,000,000 -47,000,000 -42,000,000 -34,000,000 -24,000,000 0 -33,000,000 0 -20,000,000 0 -26,000,000 -26,000,000 -19,000,000 0 0 0 -18,000,000 0 0 0 -12,600,000 0 -34,200,000 -23,800,000 -28,000,000 0 
          free cash flows
        		-38,000,000 46,000,000 127,000,000 180,000,000 -69,000,000 130,000,000 120,000,000 166,000,000 -22,000,000 157,000,000 165,000,000 61,000,000 -165,000,000 13,000,000 163,000,000 286,000,000 -81,000,000 223,000,000 89,000,000 149,000,000 4,000,000 -92,900,000 -111,700,000 159,300,000 -8,300,000 126,300,000 5,400,000 28,800,000 -22,400,000 139,500,000 
          cash flows from investing activities
        		                              
          net purchases of property and equipment and software
        		-51,000,000 -62,000,000 -92,000,000 -57,000,000 -65,000,000 -47,000,000 -42,000,000 -34,000,000 -24,000,000  -33,000,000                    
          proceeds from divestitures
        		 0 0 0 9,000,000                          
          other investing activities
        		-9,000,000 -2,000,000 -9,000,000 1,000,000 -2,000,000  0   6,000,000 0 -1,000,000 -1,000,000 1,000,000 -2,000,000 -4,000,000 -3,000,000 0 -1,000,000 0 -7,000,000 900,000 -6,700,000 -900,000 -400,000 36,800,000 -16,000,000 -25,200,000 -500,000 2,700,000 
          net cash from investing activities
        		-60,000,000 -64,000,000 -101,000,000 -56,000,000 -58,000,000 -90,000,000 1,244,000,000 -33,000,000 37,000,000 -35,000,000 -36,000,000 -43,000,000 -55,000,000 -76,000,000 -37,000,000 -37,000,000 -29,000,000 -74,000,000 -441,000,000 -25,000,000 10,000,000 -73,300,000 -4,696,900,000 10,600,000 -19,600,000 -74,300,000 -83,000,000 -49,000,000 -28,500,000 -48,100,000 
          cash flows from financing activities
        		                              
          proceeds from revolving credit facility
        		 0 0 0 125,000,000 0 0 0 50,000,000 0 100,000,000 50,000,000 200,000,000 0 0 500,000,000 63,000,000              
          repayments of revolving credit facility
        		 0 0 0 -125,000,000 0 0 -200,000,000 -50,000,000 -97,000,000    0 -75,000,000 -575,000,000 -163,000,000              
          proceeds from securitization facility
        		 0 0 0 125,000,000 0 0 120,000,000 50,000,000 0                     
          repayments of securitization facility
        		 0 0 -85,000,000 -40,000,000 -25,000,000 -120,000,000 0 -50,000,000 -28,000,000                     
          repayments of long-term borrowings
        		-16,000,000 -2,107,000,000 -188,000,000 -361,000,000 -13,000,000 -13,000,000 -1,562,000,000 -12,000,000 -13,000,000 -14,000,000 -356,000,000 -13,000,000 -19,000,000 -70,000,000 -79,000,000 -439,000,000 -89,000,000              
          shares repurchased for employee tax withholdings
        		-34,000,000                              
          other financing activities
        		-15,000,000 -17,000,000 35,000,000 0 -20,000,000 6,000,000 -8,000,000 -1,000,000 -14,000,000 0 -1,000,000 2,000,000 -7,000,000 1,000,000 0 -6,000,000 -11,000,000 -12,000,000 0 0 -17,000,000 -1,000,000 -1,000,000 -1,400,000 -12,800,000 -100,000 300,000 1,900,000 -500,000 -13,500,000 
          net cash from financing activities
        		-65,000,000 -18,000,000 -153,000,000 -156,000,000 52,000,000 -32,000,000 -1,340,000,000 -93,000,000 -27,000,000 -139,000,000 -157,000,000 39,000,000 174,000,000 -84,000,000 -169,000,000 -96,000,000 -200,000,000 44,000,000 231,000,000 -67,000,000 2,000,000 -18,300,000 4,068,300,000 7,300,000 896,600,000 -6,200,000 -48,800,000 89,700,000 -339,500,000 -362,400,000 
          effect of exchange rate changes on cash and cash equivalents
        		-5,000,000 14,000,000 1,000,000 27,000,000 29,000,000 -77,000,000 8,000,000 -3,000,000 -19,000,000 0 -3,000,000 -8,000,000 -1,000,000 32,000,000 -30,000,000 -14,000,000 -5,000,000 -8,000,000 -6,000,000 8,000,000 -25,000,000 19,300,000 9,100,000 7,500,000 -9,300,000 -21,000,000 15,900,000 2,700,000 -14,500,000 13,600,000 
          net increase in cash and cash equivalents
        		-117,000,000 40,000,000 -34,000,000 52,000,000 19,000,000 -22,000,000 74,000,000   -17,000,000 2,000,000     165,000,000 -296,000,000              
          cash and cash equivalents – beginning of period
        		545,000,000  0 0 468,000,000  0 0 352,000,000  0                    
          cash and cash equivalents – end of period
        		428,000,000  -34,000,000 52,000,000 487,000,000  74,000,000 71,000,000 345,000,000  2,000,000                    
          goodwill impairment
        		         0                     
          deferred income taxes
        		            2,000,000 -21,000,000 4,000,000 -29,000,000 -11,000,000              
          asset impairment and write-down charges
        		 47,000,000    5,000,000 15,000,000   27,000,000    -6,000,000 0 59,000,000 28,000,000 5,000,000 56,000,000            
          gain on divestiture
        		     0                         
          proceeds from interest rate swap settlements
        		     0    0    0 75,000,000                
          other changes in operating assets and liabilities, net of acquisitions and divestitures:
        		                              
          receivables
        		                              
          inventories
        		                             -1,028,800,000 
          other assets
        		                              
          accounts payable and other liabilities
        		                              
          cash paid for acquisitions
        		     -36,000,000 0 0 -5,000,000  -3,000,000 0 -16,000,000                  
          proceeds from issuance of long-term debt
        		     0        0 0   0    250,000,000 4,475,000,000 0 79,200,000     22,300,000 
          proceeds from sale of future revenue, net of transaction costs
        		 0 0                            
          cash and cash equivalents at january 1
        		            345,000,000  0 0 638,000,000              
          cash and cash equivalents at december 31
        		                              
          changes in operating assets and liabilities, net of acquisitions and divestitures
        		  59,000,000 52,000,000 -237,000,000  248,000,000 22,000,000 -177,000,000                      
          supplemental disclosure of non-cash investing and financing activities:
        		                              
          right-of-use assets obtained in exchange for new finance lease liability
        		  -8,000,000                            
          loss on extinguishment of debt
        		             1,000,000 2,000,000                
          purchases of intangible assets
        		     -6,000,000    0 0 0 -14,000,000 -2,000,000 -10,000,000   -3,000,000 -1,000,000 -1,000,000 -33,000,000          
          proceeds from aqua business divestiture
        		                              
          proceeds from sale of shawnee and speke facilities
        		       0 66,000,000                      
          funding related to construction of corporate headquarters
        		                              
          proceeds from business divestitures
        		                              
          proceeds from previous sale of shawnee and speke facilities
        		                              
          net decrease in cash and cash equivalents
        		        -7,000,000    -27,000,000                  
          net loss
        		         -141,000,000    -55,000,000     -104,000,000 -210,000,000 -61,000,000          
          adjustments to reconcile net loss to cash flows from operating activities:
        		                              
          inventory fair value step-up amortization
        		            1,000,000     0 1,000,000 1,000,000 62,000,000          
          other changes in operating assets and liabilities
        		                            -127,600,000  
          purchases of property and equipment and software
        		                              
          cash paid for acquisitions, net of cash acquired
        		                 0 -415,000,000 0 73,000,000 0    0     
          changes in operating assets and liabilities, net of acquisitions
        		          27,000,000 -34,000,000 -439,000,000      -53,000,000 -7,000,000 -183,000,000          
          loss on sale of assets
        		            1,000,000 2,000,000 2,000,000                
          net purchases of property and equipment
        		            -20,000,000  -26,000,000 -26,000,000 -19,000,000    -18,000,000    -12,600,000  -34,200,000 -23,800,000 -28,000,000  
          purchases of software
        		            -4,000,000 -11,000,000 -10,000,000 -6,000,000 -7,000,000 -22,000,000 1,000,000 -7,000,000 -5,000,000 -28,500,000 -88,200,000 -27,800,000 -31,800,000      
          cash and cash equivalents at march 31
        		            318,000,000    342,000,000              
          loss on divestitures
        		                 -1,000,000             
          purchases of property and equipment
        		                              
          disposals of property and equipment
        		                              
          divestiture proceeds
        		                     0         
          proceeds from issuance of common stock and tangible equity units
        		                     0 0 0 1,219,900,000      
          debt issuance costs
        		             0 -1,000,000   -1,000,000    0 -99,300,000 -100,000 -3,100,000      
          early redemption and tender premiums paid
        		             0                 
          net increase in cash, cash equivalents and restricted cash
        		                 185,000,000 -127,000,000 65,000,000 9,000,000 -165,200,000 -731,200,000 184,700,000 872,000,000 24,800,000    -257,400,000 
          cash, cash equivalents and restricted cash at january 1
        		                 0 0 0 506,000,000 0 0 0 345,100,000 0 0 0 677,500,000 0 
          cash, cash equivalents and restricted cash at december 31
        		                              
          loss on divestiture
        		                              
          proceeds from site divestitures
        		                              
          other net financing transactions with lilly
        		                  0 0 -11,000,000    -15,200,000  1,300,000 161,400,000 -156,400,000  
          cash and cash equivalents at september 30
        		                              
          changes in operating assets and liabilities
        		               -38,000,000 -331,000,000       215,500,000 -9,800,000  -61,800,000    
          cash and cash equivalents at june 30
        		                              
          gain on sale of assets
        		                1,000,000     0 0 -47,500,000 -3,800,000      
          deferred income tax benefit
        		                              
          consideration paid to lilly in connection with the separation
        		                         0 -400,000 -16,100,000 -175,100,000 -432,200,000 
          change in deferred income taxes
        		                  -5,000,000 -82,000,000 -32,000,000 35,000,000 -81,400,000 -53,300,000 -25,100,000 -14,800,000 -25,400,000 24,000,000 16,300,000 -73,300,000 
          proceeds from settlement of net investment hedges
        		                     0 0 7,500,000 25,200,000      
          proceeds from product divestitures
        		                              
          repayments of borrowings
        		                  -518,000,000 -17,000,000 -20,000,000  -306,400,000 -6,400,000 -371,400,000 -6,100,000 -50,000,000 -57,500,000 -7,500,000  
          net proceeds from revolving credit facility
        		                    50,000,000          
          cash, cash equivalents and restricted cash at september 30
        		                              
          net proceeds from sale (purchases) of property and equipment
        		                      -35,400,000        
          cash, cash equivalents and restricted cash at june 30
        		                              
          asset impairment charges
        		                    9,000,000 20,400,000 1,200,000   7,900,000 20,700,000 0 4,000,000 18,000,000 
          cash, cash equivalents and restricted cash at march 31
        		                    515,000,000    1,217,100,000    300,600,000  
          gain on divestitures
        		                     -300,000         
          other net transactions with lilly
        		                             93,000,000 
          proceeds from issuance of common stock
        		                             0 
          cash, cash equivalents and restricted cash at september 30, 2019
        		                              
          net decrease in cash, cash equivalents and restricted cash
        		                           96,000,000 -376,900,000  
          assets
        		                              
          current assets
        		                              
          cash and cash equivalents
        		                              
          accounts receivable, net of allowances of 8.8
        		                              
          other receivables
        		                              
          prepaid expenses and other
        		                              
          restricted cash
        		                              
          total current assets
        		                              
          noncurrent assets
        		                              
          investments
        		                              
          goodwill
        		                              
          other intangibles
        		                              
          other noncurrent assets
        		                              
          property and equipment, net of accumulated depreciation 894.5
        		                              
          total assets
        		                              
          liabilities and equity
        		                              
          current liabilities
        		                              
          accounts payable
        		                              
          employee compensation
        		                              
          sales rebates and discounts
        		                              
          other current liabilities
        		                              
          payable to lilly
        		                              
          total current liabilities
        		                              
          noncurrent liabilities
        		                              
          long-term debt
        		                              
          accrued retirement benefits
        		                              
          deferred taxes
        		                              
          other noncurrent liabilities
        		                              
          total liabilities
        		                              
          commitments and contingencies
        		                              
          equity
        		                              
          net parent company investment
        		                              
          common stock, no par value, 5,000,000,000 shares authorized 365,625,000 shares issued and outstanding as of september 30, 2018
        		                              
          additional paid-in capital
        		                              
          accumulated other comprehensive loss
        		                              
          total equity
        		                              
          total liabilities and equity
        		                              
          december 31, 2016
        		                              
          other comprehensive income, net of tax
        		                              
          transfers (to)/from lilly
        		                              
          september 30, 2017
        		                              
          december 31, 2017
        		                              
          adoption of accounting standards update 2016-16
        		                              
          separation adjustments
        		                              
          issuance of common stock
        		                              
          consideration to lilly in connection with the separation
        		                              
          reclassification of net parent company investment
        		                              
          september 30, 2018
        		                              
          other changes in operating assets and liabilities, net of acquisitions and divestitures